First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma

Neuro-Oncology

Volumn 11, Issue 4, 2009, Pages 423-429

  Maza, Sofiane ^a   Kiewe, Philipp ^a   Munz, Dieter L ^a   Korfel, Agnieszka ^a   Hamm, Bernd ^a   Jahnke, Kristoph ^a   Thiel, Eckhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

90Y ibritumomab tiuxetan; CNS lymphoma; Imaging; PCNSL; Zevalin

Indexed keywords

DEXAMETHASONE; IBRITUMOMAB TIUXETAN; INDIUM 111; RITUXIMAB;

ADULT; AGED; ARTICLE; BUERGER DISEASE; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; RADIOIMMUNOTHERAPY; RECURRENT CANCER; SEPSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; RADIOIMMUNOTHERAPY; REMISSION INDUCTION; SURVIVAL RATE; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 68949125214     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-108     Document Type: Article

References (14)

1. DeAngelis LM. Primary CNS lymphoma: Treatment with combined chemotherapy and radiotherapy. J Neurooncol. 1999;43:249-257.
2. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood. 1998;92:1927-1932.
3. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
4. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood. 2003;101:466-468.
5. Ott RJ, Brada M, Flower MA, et al. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer. 1991;27:1356-1361.
6. Abrey LE, Batchelor TT, Ferreri AJ, et al. International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-5043.
7. Dietlein M, Pels H, Schulz H, et al. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol. 2005;74:348-352.
8. Iwamoto FM, Schwartz J, Pandit-Taskar N, et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer. 2007;110:2528-2534.
9. Sakamoto M, Oya N, Mizowaki T, et al. Initial experiences of palliative stereotactic radiosurgery for recurrent brain lymphomas. J Neurooncol. 2006;77:53-58.
10. Doolittle ND, Jahnke K, Belanger R, et al. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma. 2007;48:1712-1720.
11. Shah JJ, Meredith R, Shen S, et al. Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy. Clin Lymphoma Myeloma. 2006;7:236-238.
12. Pitini V, Baldari S, Altavilla G, Arrigo C, Naro C, Perniciaro F. Salvage therapy for primary central nervous system lymphoma with (90) Y-ibritumomab and temozolomide. J Neurooncol. 2007;83:291-293.
13. Ferrucci PF, Vanazzi A, Tesoriere G, et al. Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement. Ann Oncol. 2005;16:1710-1711.
14. CTCAE. Common Terminology Criteria for Adverse Events version 3.0 Online Instructions and Guidelines. Available at https://webapps.ctep.nci.nih.gov/ webobjs/ctc/webhelp/welcome-to-ctcae.htm. Accessed May 11, 2009.